BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design

J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):177-179. doi: 10.1093/jpids/piad005.


In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47-69] <3 months post-dose-two and 28% [8-43] after ≥3 months. A booster improved protection to 77% [53-88].

Keywords: BNT162b2; COVID-19; Kaiser Permanente; SARS-CoV-2; United States; booster; delta; effectiveness; omicron; pediatric; real-world; test-negative.

MeSH terms

  • BNT162 Vaccine*
  • COVID-19*
  • Child
  • Emergency Service, Hospital
  • Humans


  • BNT162 Vaccine

Grant support